IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease
July 10 2019 - 8:00AM
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in
pharmaceutical films, today announced that it will present a
Montelukast poster at the 12th edition of Clinical Trials on
Alzheimer’s Disease (CTAD2019), to be held in San Diego,
California, from December 4-7, 2019.
The poster, entitled “The BUENA Study: A Phase 2a Clinical Trial
to Test Safety and Efficacy of Montelukast VersaFilm®in Alzheimer’s
Patients,” will be presented in collaboration with Prof. Dr. Ludwig
Aigner’s group fromthe Paracelsus Medical University in
Salzburg.
“Our studies of Montelukast have garnered positive feedback from
the Alzheimer’s disease community to-date, so we are looking
forward to presenting our ongoing BUENA studyat CTAD2019,”said Dr.
Horst G. Zerbe, CEO of IntelGenx.
BUENA is a randomized, double-blind, placebo-controlled Phase 2a
“proof of concept” study designed to assess Montelukast VersaFilm®
in approximately 70 patients with mild to moderate Alzheimer’s
disease. BUENA will evaluate the safety, feasibility, tolerability,
and efficacy of Montelukast buccal film following daily dosing for
26 weeks.
About Montelukast VersaFilm®
Montelukast is a leukotriene receptor antagonist that was
approved by the U.S. Food and Drug Administration in 1997 for the
treatment of asthma and seasonal allergic rhinitis. IntelGenx is
working to repurpose Montelukast as a therapeutic to treat
neurodegenerative diseases by re-formulating the drug into an oral
film-based product. IntelGenx's proprietary VersaFilm® technology
is especially suited for special needs patient populations, and the
Montelukast VersaFilm® product offers many distinct advantages over
tablets for Alzheimer’s Disease patients, including the avoidance
and minimization of first-pass-effects, ease of administration,
improved API bioavailability, lower dosing and toxicity, better
acceptability and improved compliance.
In Phase 1 studies, IntelGenx demonstrated that an oral film
formulation of Montelukast is safe and tolerable in healthy
subjects, reduces the first-pass-effect and has a 52% higher
bioavailability compared to the regular Montelukast tablet,
demonstrating a clear advantage of delivering Montelukast via film.
IntelGenx's oral film also crossed the blood-brain barrier, an
essential feature for treating degenerative brain diseases.
Always Remember For Those Who Forget™.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the
development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm®,
VetaFilm™ and transdermal, allow for next generation pharmaceutical
products that address unmet medical needs. IntelGenx’s innovative
product pipeline offer significant benefits to patients and
physicians for many therapeutic conditions.
IntelGenx's highly skilled team provides comprehensive
pharmaceuticals services to pharmaceutical partners, including
R&D, analytical method development, clinical monitoring, IP and
regulatory services. IntelGenx's state-of-the-art manufacturing
facility offers full service by providing lab-scale to pilot- and
commercial-scale production. For more information, visit
www.intelgenx.com.
Forward Looking Statements
This document may contain forward-looking information about
IntelGenx's operating results and business prospects that involve
substantial risks and uncertainties. Statements that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended. These
statements include, but are not limited to, statements about
IntelGenx's plans, objectives, expectations, strategies, intentions
or other characterizations of future events or circumstances and
are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by
this cautionary statement. Because these forward-looking statements
are subject to a number of risks and uncertainties, IntelGenx's
actual results could differ materially from those expressed or
implied by these forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, those discussed under the heading "Risk Factors" in
IntelGenx's annual report on Form 10-K, filed with the United
States Securities and Exchange Commission and available
at www.sec.gov, and also filed with Canadian securities
regulatory authorities at www.sedar.com. IntelGenx assumes no
obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTCQX has neither approved
nor disapproved the contents of this press release. Neither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Source: IntelGenx Technologies Corp.
For more information, please contact:
Stephen Kilmer
Investor Relations
(514) 331-7440 ext. 232
stephen@intelgenx.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext. 203
andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Sep 2023 to Sep 2024